Colin Heitzmann is VP, Intellectual Property and Business Development at Daiichi-Sankyo Pharmaceuticals. Daiichi-Sankyo is a global pharmaceutical company focused on therapies for cancer and cardiovascular disease. In his new role, Colin is responsible for the protection of and maximization of Daiichi Sankyo’s US IP portfolio and for managing the portfolio of legal work relating to Daiichi-Sankyo’s Global and U.S. Business Department departments. Colin is a graduate of the University of Michigan Law School and worked at top law firms including Winston & Strawn before moving in house. Prior to joining Daiichi-Sankyo Colin was VP and Head of Intellectual Property at Sumitovant Biopharma.
